T-cell targeted interleukine 12 - Repertoire Immune Medicines
Alternative Names: T Cell Targeted IL-12Latest Information Update: 15 Oct 2021
At a glance
- Originator Repertoire Immune Medicines
- Class Antineoplastics; Immunotherapies; Interleukins; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 10 Feb 2021 Preclinical trials in Solid tumours in USA (Parenteral) before February 2021 (Repertoire Immune Medicines' pipeline, February 2021)